Stockreport

Candel Therapeutics Announces CAN-2409 Achieved Primary Endpoint in Phase 3 Prostate Cancer Trial, Showing Significantly Improved Disease-Free Survival [Yahoo! Finance]

Candel Therapeutics, Inc.  (CADL) 
PDF benefit when combined with radiation therapy for intermediate-to-high risk, localized prostate cancer The safety profile of CAN-2409 was generally consistent with prev [Read more]